Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

High weight and obesity are associated with poor outcomes in leukemia treatment.

2.

Climate change is expected to increase the number of suicide deaths

3.

FDA Greenlights First Engineered Cell Therapy for a Solid Tumor

4.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.

5.

Study reveals that older women frequently receive an incorrect breast cancer diagnosis.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot